Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 7, 1998, Pages 642-648

  Wong, Shekman L ^a   O'Dea, Robert F ^a   Dube, Louise M ^a   Awni, Walid M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRELEUTON; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; LIPOXYGENASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; PHASE 1 CLINICAL TRIAL;

EID: 0031879376     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04472.x     Document Type: Article

References (15)

1. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al: The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. New Engl J Med 1990;323:1740-1744.
2. Bolt HM: Interactions between clinically used drugs and oral contraceptives. Environ Health Perspect 1994;102(Suppl 9):35-38.
3. Wong SL, Drajesk J, Chang M, Witt G, Awni WM: Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761 in healthy volunteers. Biopharm Drug Disp 1998;19:159-162.
4. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Mercel Dekker, 1982.
5. Back DJ, Madden S, Orme ML'E: Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol 1990;163:2138-2145.
6. Orme ML, Back DJ, Ball S: Interindividual variation in the metabolism of ethynylestradiol. Pharmacol Ther 1989;43:251-260.
7. Back DJ, Breckenridge AM, Maclver M, Orme ML'E, Purba HS, Rowe PH: The interaction of ethinyloestradiol with ascorbic acid in man. Br Med J 1981;282:1516.
8. Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme ML'E: paracetamol interaction with oral contraceptives steroids: increased plasma concentrations of ethinyloestradiol. Br J Clin Pharmacol 1987;23:721-725.
9. D'Arcy: Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986;20:353-362.
10. Orme ML'E, Back DJ: Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 1990; 163:2146-2152.
11. Goldzieher JW: Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet Gynecol 1990;163:318-322.
12. Fotherby K: Interactions with oral contraceptives. Am J Obstet Gynecol 1990;163:2153-2159.
13. Wong SL, Drajesk J, Chang M, Lanni C, Witt G, Hansen R, Awni WM: Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. Clin Pharmacol Ther 1998;63:324-331.
14. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme ML'E: The interactions of phenytoin and carbamazepaine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30:892-896.
15. Back DJ, Breckenridge AM, Crawford FE, Hall JM, Maclver M, Orme ML'E, et al: The effects of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980;21:135-143.